Onychomycosis Market Report and Forecast 2024-2032

Onychomycosis Market Outlook

The onychomycosis market size was valued at USD 4 billion in 2023 in the 7 major markets, driven by the rising prevalence of onychomycosis especially in the geriatric population across the major markets. The market size is anticipated to grow at a CAGR of 5.2% during the forecast period of 2024-2032 to achieve a value of USD 6.3 billion by 2032.

Onychomycosis: Introduction

Nail fungus is a common nail infection that initiates as a white or yellow-brown spot under the tip of the fingernail or toenail. The nail starts discoloring, thickening, and crumbling at the edge as the infection goes deep. Nail fungus is also called onychomycosis. When fungus infects the areas between the toes and the skin of the feet, it's called athlete's foot (tinea pedis).

Developments such as oral antifungal drugs like itraconazole (Sporanox), stimulate new nail growth free of infection, slowly replacing the infected part. Another innovation is medicated nail polish ciclopirox (Penlac) prescribed by healthcare professionals to be used once a day for as long as 6 weeks or more. Additionally, medicated nail cream, more of an antifungal cream such as efinaconazole (Jublia) and tavaborole (Kerydin) also works as effective treatments for this nail condition.

Onychomycosis Market Analysis

The increasing number of clinical developments to treat onychomycosis is a major trend influencing the market growth. Such developments by key players are boosting the demand for treatment for onychomycosis, further boosting the onychomycosis market growth.  The increasing approvals of drugs by regulatory bodies for the treatment of onychomycosis are influencing the market growth as well. The increasing investments by pharmaceutical companies in research and development activities to develop novel therapies are majorly expected to drive market growth as well.

The increasing research and development activities to find new treatments or study existing treatments to find their efficacy while looking for scope for improvement are also responsible for the market growth. For example, a meta-analysis study exhibited the efficacy of terbinafine, posted on Oxford Academic. The study mentioned how the efficacy of treatment with terbinafine increased with the increase in treatment duration which was 12 weeks expanded to 24 weeks.

Onychomycosis Market Segmentations

Market Breakup by Treatment Type

• Drugs

• Laser Therapy

• Photodynamic Therapy

• Others

Market Breakup by Type

• Distal Subungual Onychomycosis

• White Superficial Onychomycosis

• Proximal Subungual Onychomycosis

• Other Types

Market Breakup by Route of Administration

• Oral

• Topical

Market Breakup by End User

• Hospitals

• Dermatology and Podiatry Clinics

• Offline Pharmacies

• Online Stores

Market Breakup by Region

• United States

• EU-4 and the United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom

• Japan

Onychomycosis Market Overview

The increasing prevalence of onychomycosis is a major factor driving the market growth. The prevalence of onychomycosis is great among older people with certain risk factors such as diabetes and weakened immune systems. The market is also driven by the continuous research and developments by key players in the market to develop effective and innovative treatments coupled with increased investments. The increased number of clinical trials to find the efficacy of antifungal drugs for the treatment of onychomycosis such as terbinafine, itraconazole, and fluconazole is also responsible for the onychomycosis market growth.

The increasing awareness about onychomycosis and its treatment options among patients and healthcare providers which helped the patients to get the condition diagnosed on an early basis and get treated, further increasing the demand for medications in the market. This awareness is greatly expected to further influence the market growth. The widespread availability of improved healthcare infrastructure has also played a vital role in the market growth as people are able to access the healthcare facility nearest to them and get better treatment options.

Onychomycosis Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• Merck & Co., Inc.

• Teva Pharmaceutical Industries Ltd.

• Cipla Inc.

• Bayer AG

• Pfizer Inc.

• Abbott

• Novartis AG

• Sun Pharmaceutical Industries Ltd.

• Bausch Health Companies Inc.

• GSK Plc.

Key Highlights of the Report